生物医药公司Trevi Therapeutics Inc.（TRVI）今日盘中股价大跌5.21%，引发市场关注。该公司刚刚公布了截至6月30日的季度业绩报告，显示业绩表现不及市场预期。
根据财报，Trevi Therapeutics第二季度调整后每股亏损9美分，虽然较去年同期的每股亏损12美分有所改善，但仍未达到分析师平均预期的每股亏损10美分。公司当季亏损1230万美元，收入为零。值得注意的是，尽管季度业绩不佳，但Trevi Therapeutics的股价在过去一个季度上涨了32.9%，今年迄今为止已上涨76.5%。
分析认为，尽管Trevi Therapeutics的亏损幅度有所收窄，但仍未能达到市场预期，这可能是导致股价下跌的主要原因。投资者可能对公司的盈利能力产生了担忧，尤其是在收入仍为零的情况下。然而，考虑到公司股价今年以来的强劲表现，今日的下跌也可能部分源于投资者的获利了结。此外，分析师对公司的平均评级仍维持在"买入"，12个月目标价中位数为22.00美元，远高于当前股价，这表明市场对公司的长期前景仍持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.